Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956406 | 0.88 | — | — | |
| SCHEMBL11173515 | 0.85 | GAA (0.33) | GAATDP1 | |
| SCHEMBL31258233 | 0.84 | GAA (0.32) | GAATDP1 | |
| SCHEMBL11172923 | 0.80 | F2 (0.41) | GAATDP1ENPP2SMN1; SMN2MEN1 | |
| SCHEMBL26864510 | 0.79 | USP2 (0.34) | GAATDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14350870 | 0.79 | GAA (0.31) | GAATDP1 | |
| SCHEMBL18803321 | 0.78 | USP2 (0.32) | GAAMAPT | |
| SCHEMBL4923753 | 0.75 | MAPT (0.31) | MAPT | |
| SCHEMBL8115315 | 0.75 | PKM (0.34) | — | |
| SCHEMBL11652182 | 0.74 | HPGD (0.46) | GAATDP1ENPP2SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-05 | — | — | US | disclosed |
| EP-2037922-A2 | PROLYL HYDROXYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150011-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-1081140-B1 | Novel Pyrimidine-2,4,6-trione compounds | DSM IP ASSETS BV (NL) | 2005-06-01 | — | — | EP | disclosed |
| US-6573269-B1 | Compounds for protecting surface of substrate from ultraviolet light | ROCHE VITAMINS INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1081140-A2 | Novel Pyrimidine-2,4,6-trione compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| US-6114546-A | Aminomethylene derivatives and ultraviolet absorbent comprising thereof | CHEMIPRO KASEI KAISHA, LIMITED (JP) | 2000-09-05 | — | — | US | disclosed |
| CN-1236357-A | Aminomethylene derivatives and ultraviolet absorber comprising the same | CHEMIPRO KASEI KAISHA LTD (JP) | 1999-11-24 | — | — | CN | disclosed |
| EP-0950655-A1 | AMINOMETHYLENE DERIVATIVES AND ULTRAVIOLET ABSORBER COMPRISING THE SAME | CHEMIPRO KASEI KAISHA, LIMITED (JP) | 1999-10-20 | — | — | EP | disclosed |
| EP-0266882-A2 | Second harmonic generation with N,N'-substituted barbituric acids | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4714838-A | USING LASER AS SOURCE OF COHERENT LIGHT | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | GAA 224/4885TDP1 2430/4885ENPP2 2425/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | GAA 224/4885TDP1 2430/4885ENPP2 2425/4885 |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | GAA 224/4885TDP1 2430/4885ENPP2 2425/4885 |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | GAA 224/4885TDP1 2430/4885ENPP2 2425/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | GAA 224/4885TDP1 2430/4885ENPP2 2425/4885 |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | GAA 224/4885TDP1 2430/4885ENPP2 2425/4885 |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | GAA 224/4885TDP1 2430/4885ENPP2 2425/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | GAA 224/4885TDP1 2430/4885ENPP2 2425/4885 |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | GAA 224/4885TDP1 2430/4885ENPP2 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.